NEW YORK, February 22, 2017 /PRNewswire/ --
Today's research on Stock-Callers.com brings investors' attention tothe Biotech space which focuses on novel drug developments and clinical researches aimed at treating diseases and medical conditions. Up for review this morning are: Neuralstem Inc. (NASDAQ: CUR), Catalyst Biosciences Inc. (NASDAQ: CBIO), Trevena Inc.
Germantown, Maryland headquartered Neuralstem Inc.'s stock finished Tuesday's session 2.17% lower at $3.61. A total volume of 855,689 shares was traded, which was above their three months average volume of 558,520 shares. The Company's shares have advanced 2.85% on an YTD basis. The stock is trading below its 50-day moving average by 0.89%. Furthermore, shares of Neuralstem, which focuses on the research, development, and commercialization of central nervous system therapies based on its proprietary human neuronal stem cells and stem-cell derived small molecule compounds, have a Relative Strength Index (RSI) of 53.62.
On February 16th, 2017, Neuralstem announced completion of subject enrollment in its Phase-2 clinical trial of NSI-189 for the treatment of major depressive disorder. NSI-189 is a new chemical entity and the lead compound in Neuralstem's neurogenic small molecule program. The Company noted that enrollment was completed ahead of schedule and data are expected in Q3 2017. Access our complete research report on CUR for free at:
Shares in South San Francisco, California headquartered Catalyst Biosciences Inc. ended at $6.87, down 1.01% from the last trading session. The stock recorded a trading volume of 66,074 shares. The Company's shares have skyrocketed 1,064.41% in the last one month, 854.17% over the previous three months, and 956.92% since the start of this year. The stock is trading 413.18% above its 50-day moving average and 448.36% above its 200-day moving average. Moreover, shares of Catalyst Biosciences, which focuses on engineering proteases as therapeutics for hemophilia, hemeostasis, complement-mediated diseases, and other unmet medical needs, have an RSI of 74.05.
On February 16th, 2017, Catalyst Biosciences announced that Andrew Hetherington has been promoted to Senior Vice President of Technical Operations. The Company noted that Mr. Hetherington joined Catalyst in September 2015 and has successfully led the Pfizer-to-Catalyst technology transfer of the Company's next-generation Factor VIIa clinical candidate, and has been instrumental in advancing the Company's next generation Factor IX clinical manufacture and associated program activities. The complimentary research report on CBIO can be downloaded at:
King of Prussia, Pennsylvania-based Trevena Inc.'s stock ended yesterday's session 40.11% lower at $4.27. A total volume of 10.48 million shares was traded, which was above their three months average volume of 523,770 shares. The Company's shares are trading 34.42% below their 50-day moving average. Additionally, shares of Trevena, which discovers, develops, and intends to commercialize therapeutics for G protein coupled receptors, have an RSI of 21.36.
On February 02nd, 2017, research firm Ladenburg Thalmann initiated a 'Buy' rating on the Company's stock, with a target price of $15 per share.
On February 21st, 2017, Trevena announced positive top-line results from its Phase-3 APOLLO-1 and APOLLO-2 pivotal efficacy studies of oliceridine in moderate-to-severe acute pain following bunionectomy and abdominoplasty, respectively. The Company noted that in both studies, all dose regimens achieved their primary endpoint of statistically greater analgesic efficacy than placebo, as measured by responder rate. In addition, oliceridine showed dose-related trends of improvements versus morphine on numerous measures of respiratory safety and gastrointestinal tolerability - both key unmet needs in acute pain management. Register for free on Stock-Callers.com and get access to the latest PDF format report on TRVN at:
At the close of trading on Tuesday, shares in San Francisco, California headquartered FibroGen Inc. recorded a trading volume of 262,086 shares. The stock finished 1.02% lower at $24.35. The Company's shares have gained 8.22% in the previous three months and 13.79% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 6.68% and 23.53%, respectively. Furthermore, shares of FibroGen, which discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs, have an RSI of 57.43.
On February 03rd, 2017, FibroGen announced that clinical results from the Company's open-label, dose-escalation Phase-1/2 study (FGCL-MC3019-028) of pamrevlumab in pancreatic cancer were published in the Journal of Cancer Clinical Trials. FibroGen noted that the published results support a dose-related increase in survival in advanced pancreatic cancer, and that pamrevlumab can be safely combined with chemotherapy. Pamrevlumab is first-in-class fully human monoclonal therapeutic antibody that inhibits connective tissue growth factor, a common factor in chronic fibrotic and proliferative disorders. Download your free research report on FGEN at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: email@example.com Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!